Argadin
Also known as: Argadin cyclic pentapeptide, Cyclo(Arg-Pro-Pro-Tyr-Ile)
Summary
Argadin is a naturally occurring cyclic pentapeptide originally isolated from the fungus Chromocyphella muscicola. It is a potent inhibitor of chitinase enzymes and has been studied as a potential therapeutic lead for asthma and other inflammatory conditions where chitinases play a pathological role. It remains a research tool compound with no approved clinical use.
Mechanism of Action
Competitive inhibitor of chitinases, particularly acidic mammalian chitinase (AMCase) and chitotriosidase; binds the active site of chitinase enzymes, blocking hydrolysis of chitin substrates
Routes of Administration
Goals & Uses
- Anti-inflammatory researchInflammationLow
- Chitinase inhibition researchBiochemical ToolModerate
- Asthma treatmentRespiratory / InflammationLow
- Drug scaffold developmentMedicinal ChemistryLow
Contraindications
No contraindications recorded yet.
Adverse Effects
- Unknown systemic toxicityGeneralUnknown
Drug Interactions
No drug interactions recorded yet.
Population Constraints
- General populationGeneralAbsolute
Regulatory Status
- European UnionUnapprovedResearch compound only; no EMA regulatory status
- United StatesUnapprovedResearch compound only; not FDA approved or under IND
- United KingdomUnapprovedResearch compound only; no MHRA regulatory status
No regulatory approvals in any jurisdiction. Used as a research tool compound to study chitinase biology and as a scaffold for drug development.
Evidence & Sources
No sources recorded yet.